Raymond James Financial
STLN

Raymond James Financial’s Starling Oncology STLN Stock Holding History

Raymond James Financial’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-35,748
Closed -$125K – 5335
2025
Q3 		$125K Buy
35,748
+33,417
+1,434% +$114K ﹤0.01% 4715
2025
Q2 		$4.78K Buy
+2,331
New +$5.83K ﹤0.01% 6185

Other funds holding STLN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $2.04B AUM 35.27% 1-Year Est. Return
KWM
Kanen Wealth Management Coconut Creek, Florida $413M AUM 109.83% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Raymond James Financial's STLN Position: Q4 2025 in Review

Raymond James Financial sold out of Starling Oncology (STLN) in Q4 2025, closing a stake of 35,748 shares — an estimated $125K sold.

Raymond James Financial first reported a position in STLN in Q2 2025 and held it in 2 quarters. The position peaked at $125K in Q3 2025. 117 funds tracked by Wall St. Rank hold STLN as of Q4 2025.

  • Raymond James Financial reported no remaining Starling Oncology position as of Q4 2025 after selling out during the quarter.
  • Raymond James Financial sold 35,748 Starling Oncology shares in Q4 2025, an estimated $125K.
  • Raymond James Financial first reported a position in Starling Oncology in Q2 2025 and held it in 2 quarters.
  • Raymond James Financial's Starling Oncology position peaked at $125K in Q3 2025.
  • 117 funds tracked by Wall St. Rank held Starling Oncology as of Q4 2025.

Based on Raymond James Financial's 13F filing for Q4 2025, filed 18 Feb 2026.